Cargando…
Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is kn...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758278/ https://www.ncbi.nlm.nih.gov/pubmed/24023672 http://dx.doi.org/10.1371/journal.pone.0073097 |
_version_ | 1782282330877984768 |
---|---|
author | Venturelli, Sascha Berger, Alexander Böcker, Alexander Busch, Christian Weiland, Timo Noor, Seema Leischner, Christian Schleicher, Sabine Mayer, Mascha Weiss, Thomas S. Bischoff, Stephan C. Lauer, Ulrich M. Bitzer, Michael |
author_facet | Venturelli, Sascha Berger, Alexander Böcker, Alexander Busch, Christian Weiland, Timo Noor, Seema Leischner, Christian Schleicher, Sabine Mayer, Mascha Weiss, Thomas S. Bischoff, Stephan C. Lauer, Ulrich M. Bitzer, Michael |
author_sort | Venturelli, Sascha |
collection | PubMed |
description | The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is known about the activity of resveratrol on the classical HDACs of class I, II and IV, although these classes are involved in cancer development or progression and inhibitors of HDACs (HDACi) are currently under investigation as promising novel anticancer drugs. We could show by in silico docking studies that resveratrol has the chemical structure to inhibit the activity of different human HDAC enzymes. In vitro analyses of overall HDAC inhibition and a detailed HDAC profiling showed that resveratrol inhibited all eleven human HDACs of class I, II and IV in a dose-dependent manner. Transferring this molecular mechanism into cancer therapy strategies, resveratrol treatment was analyzed on solid tumor cell lines. Despite the fact that hepatocellular carcinoma (HCC) is known to be particularly resistant against conventional chemotherapeutics, treatment of HCC with established HDACi already has shown promising results. Testing of resveratrol on hepatoma cell lines HepG2, Hep3B and HuH7 revealed a dose-dependent antiproliferative effect on all cell lines. Interestingly, only for HepG2 cells a specific inhibition of HDACs and in turn a histone hyperacetylation caused by resveratrol was detected. Additional testing of human blood samples demonstrated a HDACi activity by resveratrol ex vivo. Concluding toxicity studies showed that primary human hepatocytes tolerated resveratrol, whereas in vivo chicken embryotoxicity assays demonstrated severe toxicity at high concentrations. Taken together, this novel pan-HDACi activity opens up a new perspective of resveratrol for cancer therapy alone or in combination with other chemotherapeutics. Moreover, resveratrol may serve as a lead structure for chemical optimization of bioavailability, pharmacology or HDAC inhibition. |
format | Online Article Text |
id | pubmed-3758278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37582782013-09-10 Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells Venturelli, Sascha Berger, Alexander Böcker, Alexander Busch, Christian Weiland, Timo Noor, Seema Leischner, Christian Schleicher, Sabine Mayer, Mascha Weiss, Thomas S. Bischoff, Stephan C. Lauer, Ulrich M. Bitzer, Michael PLoS One Research Article The polyphenolic alcohol resveratrol has demonstrated promising activities for the prevention and treatment of cancer. Different modes of action have been described for resveratrol including the activation of sirtuins, which represent the class III histone deacetylases (HDACs). However, little is known about the activity of resveratrol on the classical HDACs of class I, II and IV, although these classes are involved in cancer development or progression and inhibitors of HDACs (HDACi) are currently under investigation as promising novel anticancer drugs. We could show by in silico docking studies that resveratrol has the chemical structure to inhibit the activity of different human HDAC enzymes. In vitro analyses of overall HDAC inhibition and a detailed HDAC profiling showed that resveratrol inhibited all eleven human HDACs of class I, II and IV in a dose-dependent manner. Transferring this molecular mechanism into cancer therapy strategies, resveratrol treatment was analyzed on solid tumor cell lines. Despite the fact that hepatocellular carcinoma (HCC) is known to be particularly resistant against conventional chemotherapeutics, treatment of HCC with established HDACi already has shown promising results. Testing of resveratrol on hepatoma cell lines HepG2, Hep3B and HuH7 revealed a dose-dependent antiproliferative effect on all cell lines. Interestingly, only for HepG2 cells a specific inhibition of HDACs and in turn a histone hyperacetylation caused by resveratrol was detected. Additional testing of human blood samples demonstrated a HDACi activity by resveratrol ex vivo. Concluding toxicity studies showed that primary human hepatocytes tolerated resveratrol, whereas in vivo chicken embryotoxicity assays demonstrated severe toxicity at high concentrations. Taken together, this novel pan-HDACi activity opens up a new perspective of resveratrol for cancer therapy alone or in combination with other chemotherapeutics. Moreover, resveratrol may serve as a lead structure for chemical optimization of bioavailability, pharmacology or HDAC inhibition. Public Library of Science 2013-08-30 /pmc/articles/PMC3758278/ /pubmed/24023672 http://dx.doi.org/10.1371/journal.pone.0073097 Text en © 2013 Venturelli et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Venturelli, Sascha Berger, Alexander Böcker, Alexander Busch, Christian Weiland, Timo Noor, Seema Leischner, Christian Schleicher, Sabine Mayer, Mascha Weiss, Thomas S. Bischoff, Stephan C. Lauer, Ulrich M. Bitzer, Michael Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title | Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title_full | Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title_fullStr | Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title_full_unstemmed | Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title_short | Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells |
title_sort | resveratrol as a pan-hdac inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758278/ https://www.ncbi.nlm.nih.gov/pubmed/24023672 http://dx.doi.org/10.1371/journal.pone.0073097 |
work_keys_str_mv | AT venturellisascha resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT bergeralexander resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT bockeralexander resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT buschchristian resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT weilandtimo resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT noorseema resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT leischnerchristian resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT schleichersabine resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT mayermascha resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT weissthomass resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT bischoffstephanc resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT lauerulrichm resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells AT bitzermichael resveratrolasapanhdacinhibitoralterstheacetylationstatusofjistoneproteinsinhumanderivedhepatoblastomacells |